Delivery Order SPE2DB22D2206-SPE2DB25FJC88
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit dose) valued at $1,385.52 with a firm fixed price arrangement. This non-competitive, non-set-aside delivery order was awarded on August 8, 2025, with an ultimate completion date of August 29, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency has awarded a delivery order valued at $2,771.04 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30. The contract, designated as non-competitive with a firm fixed price structure, is scheduled for completion by August 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order operates as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,156.56 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units per package. This is a firm fixed price delivery order with no set-aside designation, issued on August 28, 2025, with an ultimate completion date of September 19, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $1,385.52 delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) with a firm fixed price arrangement. The award, issued on August 15, 2025, with an ultimate completion date of September 8, 2025, represents a competitively awarded, non-set-aside contract with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.52 for ORGOVYX 120 mg tablets (30-count units) on July 24, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. ORGOVYX is a prescription medication used in the treatment of prostate cancer, reflecting DLA's ongoing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit of use packaging) with a firm fixed price structure. The order was competitively awarded without set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location in the same city. This delivery order is...
- This delivery order, valued at $8,313.12, was awarded on August 28, 2025, to AmerisourceBergen Drug Corp for the supply of ORGOVYX (relugolix) 120 mg tablets in quantities of 30 units. The award was made without a set-aside designation through competitive procurement and is expected to be completed by September 19, 2025. The contract utilizes firm fixed pricing and is being funded by the Defense Logistics Agency's Medical Supply Chain division to support federal medical procurement needs. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a contract ceiling value of $1,385.52. This firm fixed-price delivery order represents a non-set-aside competitive award with an ultimate completion date of August 20, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. ORGOVYX...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of ORGOVYX 120 mg tablets (30-count units) with a ceiling value of $1,385.52. This firm fixed-price delivery order, which is not set-aside designated, is expected to be completed by August 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of ORGOVYX 120 mg tablets in packages of 30 units. This is a firm fixed-price delivery order with a ceiling value of $1,385.52, with an ultimate completion date of August 19, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJC88Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,855.20 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets (30-count units). This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of August 19, 2025, represents a non-competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $1 billion pharmaceutical prime vendor agreement running through December 2026 that supports global military healthcare supply requirements. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, serves as the prime contractor on this award with no identified subcontractors. ORGOVYX (relugolix), a prescription medication used in hormone-based cancer treatment, falls within the company's extensive portfolio of specialty pharmaceuticals and medical supplies delivered through the DLA Medical Supply Chain. The DLA's Pharmaceutical Prime Vendor Global Program structure enables multiple regional awards with different contractors, and AmerisourceBergen's established relationship with the agency—coupled with its demonstrated capability to fulfill federal procurement requirements through competitive processes—positions it as a key supplier to military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 7/29/25 |